Psilocybin for Methamphetamine Addiction
ConditionMethamphetamine Use Disorder
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age25-65
SponsorKevin Murnane
About this trial
The primary purpose of this study is to preliminarily determine if the use of psilocybin to promote abstinence from methamphetamine is feasible and well tolerated in populations such as those found in Northern Louisiana. Investigators will assess the impact of psilocybin-facilitated treatment on methamphetamine abstinence, craving, negative affect, cognitive function and quality of life. Components of the psilocybin experience will also be measured (persisting effects, quality of life, challenging experiences, etc). Investigators will assess feasibility and tolerability as rates of retention and challenging experiences, among other factors.
Eligibility criteria
Qualifiers
Age 25-65 at time of signing informed consent
Identification of methamphetamine as drug of choice
Score of at least 3 on the Severity of Dependence Scale
Have been at the designated local treatment facility for at least 7 days
Disqualifiers
Meeting criteria for substance dependence diagnoses other than methamphetamine (except nicotine and cannabis) as assessed by the MINI
History of Hallucinogen Use Disorder or Hallucinogen Persisting Perceptive Disorder
Women who are pregnant, plan to become pregnant, or are breast feeding
Women who do not agree to engage in abstinence or are not using dual contraceptive methods at the time of enrollment and for the study duration
Trial design
Treatments tested in this trial
- Psilocybin 25 mg
Treatment groups
20 Participants
are divided into 1 treatment groupSponsors and collaborators
Kevin Murnane
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Sponsor institution
Source ClinicalTrials.gov